Triple-action drug retatrutide delivers major weight loss for people with diabetes, Phase III trial finds
A recent Phase III clinical trial, TRIUMPH-2, evaluated the efficacy and safety of retatrutide, a triple receptor agonist and experimental once-weekly injection being developed to treat obesity and type 2 diabetes. What sets it apart from drugs such as semaglutide (Wegovy), which targets one hormone, and tirzepatide (Zepbound), which targets two, is its ability to activate three hormone receptors…
We haven't written up this one. Medical Xpress has the full story — the link below goes straight to it.
